重大新闻！“叫花鸡”风波余波未平：店家称系临时工误操作 市场监管部门介入调查

“叫花鸡”风波余波未平：店家称系临时工误操作 市场监管部门介入调查

杭州——近日，一段名为“游客杭州买‘叫花鸡’发现里面全是泥”的视频在网络上热传，引发广泛关注。视频中，游客称自己在杭州某景区购买了三份叫花鸡，打开后却发现其中两份里面只有泥巴，没有鸡肉。此事迅速登上微博热搜，也引起了杭州市市场监管部门的重视。

据了解，事发后，杭州市上城区市场监管局立即赶赴涉事店家进行调查。经查实，该店存在将样品当做商品售卖给消费者的行为。店家负责人表示，由于假期人手不足，他们招了一批临时工。事发当天，客流量较大，可能是临时工不熟悉商品，导致将样品误给了顾客。

目前，市场监管部门已对涉事店家立案调查，并责令其整改。同时，也将该事件纳入“双随机一公开”监管机制，加强对餐饮店的日常监管，杜绝类似事件再次发生。

**“叫花鸡”**是一道历史悠久的传统名菜，相传由南宋农民发明。这道菜的做法是用荷叶、泥巴和稻草将鸡肉包裹起来，经过火烤而成。由于鸡肉经过长时间的焖制，骨肉分离，香气浓郁，因此深受人们喜爱。

然而，近年来，一些不法商家为了牟取暴利，在制作“叫花鸡”时偷工减料，以次充好，甚至出现用其他肉类冒充鸡肉的情况。这不仅损害了“叫花鸡”的招牌，也侵害了消费者的合法权益。

此次“叫花鸡”事件再次提醒餐饮店家应严格遵守食品安全法规，杜绝虚假宣传、欺诈消费者的行为。同时，消费者在购买食品时也应注意甄别，选择信誉良好的商家，并索要相关票据，以维护自身合法权益。

以下是一些网友对该事件的评论：

• “真是太过分了，这种店家就应该严厉查处！”
• “以后还是自己在家做吧，外面吃的太不放心了。”
• “建议相关部门加强监管，定期对餐饮店进行检查。”

希望这次事件能够引起有关部门的重视，加强对餐饮行业的监管，让消费者能够吃得安心、放心。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.